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There are no European recommendations on issues specifically related to lung transplantation (LTX) in cystic fibrosis (CF). The
main goal of this paper is to provide CF care team members with clinically relevant CF-specific information on all aspects of
LTX, highlighting areas of consensus and controversy throughout Europe. Bilateral lung transplantation has been shown to be an
important therapeutic option for end-stage CF pulmonary disease. Transplant function and patient survival after transplantation
are better than in most other indications for this procedure. Attention though has to be paid to pretransplant morbidity, time for
referral, evaluation, indication, and contraindication in children and in adults.This reviewmakes extensive use of specific evidence
in the field of lung transplantation in CF patients and addresses all issues of practical importance. The requirements of pre-, peri-,
and postoperative management are discussed in detail including bridging to transplant and postoperative complications, immune
suppression, chronic allograft dysfunction, infection, and malignancies being the most important. Among the contributors to this
guiding information are 19 members of the ECORN-CF project and other experts. The document is endorsed by the European
Cystic Fibrosis Society and sponsored by the Christiane Herzog Foundation.
This paper is dedicated to Gerd Do¨ring, who was a great researcher and scientist. He was also an enthusiastic participant of the
CF Winter School in Obergurgl/Austria, where the ground for this paper was laid in 2012
1. Introduction
All aspects of CF care have been optimised over recent
decades and survival continues to progressively improve;
end-stage respiratory insufficiency at an adult age remains
the cause of death in the vast majority of CF patients. CF
constitutes the thirdmajor indication for lung transplantation
(LTX) after emphysema and pulmonary fibrosis. LTX has the
potential to significantly extend survival and improve quality
of life (QoL) provided that candidates are referred on time
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to the transplant centre and carefully selected. Since CF is
a multiorgan disease, various particularities and CF-specific
complications must be taken into consideration before and
after LTX, which requires a close cooperation between CF
paediatricians/pulmonologists and the transplant team.
This paper was initiated in March 2012 in Ober-
gurgl/Austria during a workshop on LTX in CF. A first draft
in German was compiled based on the experts’ workshop
presentations and was subsequently translated into English.
This English version was presented to a wider audience at
an ECORN-CF (ECORN-CF: European Centres of Reference
Networks for Cystic Fibrosis (ecorn-cf.eu)) meeting during
the ECFS conference in Dublin/Ireland in June 2012 and
working groups were established to subsequently develop
the various subsections. This revision was done according to
a modified (simplified to two iterations) Delphi procedure
among all participants. A final revision meeting took place
in April 2013 in Frankfurt/Germany.
The paper was compiled to present the latest develop-
ments in science and technology in the field of LTX for
CF with particular emphasis on candidate selection, surgical
preparation, and long-term care. It is intended to serve CF
care team members as a guide and assist them in counselling
CF patients and their families on all aspects of LTX. Since
this paper was prepared by a European working group, some
information given is more Europe specific and might not
apply to other areas.
Questions on issues that are not included in this paper
due to a lack of scientific references may be asked online at
http://www.ecorn-cf.eu/.
2. Epidemiology of LTX for CF
Approximately 3700 lung transplantations are recorded
worldwide per year by the International Society for Heart
and Lung Transplantation (ISHLT) [1]. Since ISHLT reg-
istry is voluntary, the actual number of transplantations
is assumed to be higher. Detailed data on waiting lists,
number of transplantations, and mortality are available
(http://www.ishlt.org/).
The main indications for bilateral LTX are at present
emphysema (27%), CF (26%), and idiopathic pulmonary
fibrosis (17%). For various reasons the relative proportion of
CF LTX recipients is higher in Europe as compared to the
United States (US) [1].
In the cohort of all LTX recipients transplanted world-
wide from 1994 to 2010, the median actuarial survival after
LTX was 6.7 years; for patients, who had survived the first
year, the median actuarial survival increased to 9.4 years. For
CF LTX recipients thesemedian actuarial survival times were
7.5 and 10.4 years, respectively [1].
3. Preparation for LTX
Please note that the preparation procedures vary from coun-
try to country.
3.1. Formal Referral to the Transplant Centre. Given the
shortage of organs, the resulting waiting times, and the
unpredictable evolution of end-stage CF, CF patients eligible
for LTX should be referred to a transplant centre at an
appropriate time. An FEV
1
< 30% of predicted values and/or
a rapid decline in FEV
1
despite optimal conservative treat-
ment, malnutrition, and diabetes, female gender, frequent
exacerbations and/or an increasing need for intravenous
antibiotherapy, recurrent, massive hemoptysis, which cannot
be controlled by bronchial artery embolisation, relapsing or
complicated pneumothorax, or the need for ICU admission
are all indicators that a pretransplant assessment is warranted
[2, 3]. The patient’s individual motivation, current QoL, and
social environment need to be taken into consideration as
well [2, 4, 5].
The patient must be fully informed about the long-term
medical, psychological, and social effects of the anticipated
transplantation. His explicit request for LTX, documented by
written consent, is a fundamental prerequisite before being
listed in some countries. Children and adolescents may not
be listed against their will. Guidelines pertaining to this issue
have been released in some countries [6].
3.2. Determination of the Suitable Time for Listing. Presen-
tation at the transplant centre and admission to the waiting
list are two separate decision steps. Pretransplant assessment
should be carried out when there are indicators of a negative
evolution but does not necessarily result in immediate listing.
Acceptance onto the waiting list becomes necessary when
LTX is likely to prolong life and improveQoLwhen compared
to conservative medical treatment [7, 8]. Listing should
happen when estimated life expectancy is reduced, but also
at a time when it is still superior to the expected waiting
time [2]. Expected waiting time may vary widely according
to country, blood group, and height and these parameters
should be taken into account. Still, it remains very difficult to
reliably assess prognosis for an individual patient. Statistical
and mathematical approaches with multivariate models for
survival in the CF have not been able to identify robust
predictors [3]. Country specific allocation systems play a
crucial role in the decision when to list.
During the waiting period, the patient should pursue an
active lifestyle in order to maintain muscle and bone mass
and at least stabilise his nutritional condition. Vaccinations
should be completed or boosted as needed.The social support
network for the perioperative and postoperative phase should
be strengthened and emotional preparation for the transplan-
tation should be accomplished with professional help. At the
same time continuous reevaluation of the medical situation
is essential to make sure that any deterioration of health
is detected and treated early on and results in a potential
adaptation of the waiting list position (see below) [4].
3.3. Allocation ofDonor Lungs. Eligible patients are put on the
waiting list at their local transplant centre. In most European
countries, they are then notified to an organ procurement
organisation which assigns available donor lungs according
to predetermined criteria. The process of organ distribution
is called “organ allocation.” Allocation criteria may be based
on geography (regional, national, and international), urgency
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(e.g., by audit process, individual decision, or objectively by a
score system) or on waiting time, or a combination of several
criteria.
Eurotransplant (http://www.eurotransplant.org/) is the
largest organ procurement organisation in Europe, com-
prising Austria, Belgium, Croatia, Germany, Luxembourg,
The Netherlands, Slovenia, and—from July 2013 onwards—
Hungary. Spain and Portugal have their own network, as do
the Scandinavian countries, France, and the UK.
Historically, lung allocation, in the US and the Eurotrans-
plant region, was mainly based on waiting time. Recently,
though, in the context of a high mortality of patients waiting
for LTX (mainly of patients affected by pulmonary arterial
hypertension and pulmonary fibrosis), a lung allocation score
(LAS) has been devised [9]. The LAS takes into account
the estimated survival benefit offered by LTX by 1 year after
surgery and medical urgency. Since its introduction as a tool
for donor lung allocation in the US in 2005, the number of
LTX for US CF patients has increased by ∼25%. Of note, 70%
of wait-listed CF patients were transplanted after a waiting
period of 1 year decreasing the 1-year waiting-list mortality
from 15% to 10% [10]. The LAS system has also been recently
adopted in Germany for LTX candidates age 12 and older. In
the rest of the Eurotransplant region donor lung allocation
is currently still based on waiting time and/or patient status.
When waiting time is used, listing should be early.
3.4. Preoperative Examinations. An extensive work-up is
necessary in preparation for LTX. Table 1 shows the common
prerequisites and others that may be necessary according to
the individual circumstances (e.g., right heart catheterisa-
tion) [2, 4, 11]. The results of this work-up may also help
improve the baseline condition prior to LTX. Exampleswould
be an improved nutritional status, better physical fitness
through physiotherapy and rehabilitation, or the treatment of
a potential focus of infection (e.g., paranasal sinuses, teeth).
3.5. Impact of Pretransplant Upper Airways Colonisation on
LTX Outcomes. Colonisation of the transplanted lung with
pathogens such as Pseudomonas aeruginosa (P.a.) may dam-
age the allograft both directly and indirectly and probably
constitutes a risk factor for chronic lung allograft dysfunction
(CLAD) (see below) [12]. Pathogens cross colonise between
upper and lower airways in CF [13, 14] and strains recovered
from the transplant may be genotypically identical to those
colonising the upper airways and paranasal sinuses [14, 15].
It is not clear whether conservation and/or surgical methods
may prevent graft recolonisation. Surgical approaches have
been advocated in order to eradicate paranasal sinus infection
either before or immediately after LTX. However, since the
mucous membranes of the paranasal sinuses also show the
CFTR gene defect, the underlying problem of defective
mucociliary clearance cannot be surgically eliminated and
in any case upper airway colonisation cannot be surgically
eliminated either [16]. To date, there are no reports to indicate
that survival rates of CF LTX recipients with and without
prophylactic pre- or posttransplant sinus surgery differ [17].
Additional studies are required to evaluate the impact of
Table 1: Preparatory tests for LTX∗.
(i) Lab tests with blood group, HLA typing, and anti-HLA
antibodies
(ii) Assessment of vaccination status, booster injection if
necessary
(iii) Pulmonary function tests: body plethysmography,
measurement of diffusion capacity, and standardised exercise test
(iv) Chest CT without contrast agent, preferably not older than 6
months
(v) Blood gas analysis at rest
(vi) Current sputum culture
(vii) ECG, echocardiography with evaluation of pulmonary
artery pressure, and right ventricular function
(viii) Right heart catheter if necessary
(ix) Assessment of nutritional status
(x) Abdominal sonography (including recording signs of portal
hypertension), abdominal CT if necessary
(xi) Gastroscopy and colonoscopy if necessary
(xii) ENT examination, with sinus CT scan if necessary, throat
and sinus swabs if necessary
(xiii) Bone density scan
(xiv) Gynaecological/urologic screening
(xv) Psychological assessment
(xvi) Dental examination
(xvii) Presentation at ophthalmologist
(xviii) Presentation at dermatologist
(xix) Duplex sonography of the afferent arteries if necessary
(xx) Peripheral closing pressure of the ankle arteries if necessary
∗Listing reflects consensus of the ECORN-CF working group. Some centres
may request further investigations.
surgical and/or conservative elimination of sinus colonisation
on the long-term outcome after LTX.
3.6. General Absolute and Relative Contraindications to LTX.
For each eligible patient, that is, who meets the criteria for
LTX, potential contraindications should be discussed on a
case by case basis with the transplant team, but not per se
impede referral. Contraindications may evolve or become
apparent during the waiting time and so eligibility should be
regularly reconsidered.
Malignant diseases during the past 2 years are consid-
ered an absolute contraindication to LTX [2, 8], with the
exception of nonmelanoma skin tumours such as squamous-
cell and basal-cell carcinomas. Most transplant centres
demand a disease-free interval of 5 years. Serious extrapul-
monary diseases are another absolute contraindication when
combined transplantations/surgical correction is impossible.
These include severe chronic renal failure, severe hepatic
failure, and coronary artery disease that cannot be optimised
by interventional and surgical procedures or is associated
with a significantly reduced left ventricular pump function.
Furthermore, active infections, including active untreated
tuberculosis and chronic active hepatitis B, are absolute con-
traindications. Hepatitis C is only a contraindication when it
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is active and results in significant histological hepatic damage
[18, 19]. Many transplant centres include HIV infection in
the list of absolute contraindications although successful
transplantations in this setting have been carried out [20, 21].
Severe neuromuscular diseases as well as serious defor-
mations of the spinal column and chest wall and advanced
osteoporosis with fractures may constitute another group
of absolute contraindications. However, scoliosis, a frequent
finding in CF, is not a contraindication [22].
Finally, previously documented failure to adhere to med-
ical therapies or to follow-up, untreatable mental illness,
and acute or recent addictions (over the past 6 months)
such as considerable tobacco, alcohol, and substance abuse
(Table 2(a)) are absolute contraindications as well.
Malnutrition results in shorter survival after LTX in
general [23], but there is no evidence that nutritional status
does influence posttransplantation survival in CF patients
[3, 24].
Systemic steroid therapy should be tapered to <20mg
prednisolone equivalent per day before transplantation. Pre-
transplant endotracheal intubation and mechanical ventila-
tion can no longer be considered as contraindication, since
transplantation inmechanically ventilated patients with CF is
not associated with an increase in morbidity or mortality [25,
26]. In fact, invasivemechanical ventilation or extracorporeal
membrane oxygenation (ECMO) is more and more often
used as a bridge to LTX. Hemodynamic instability is at
least a relative contraindication. Other illnesses such as dia-
betes mellitus, arterial hypertension, gastroesophageal reflux
disease (GERD), and osteoporosis [24] will need optimal
management prior to transplantation. A significantly reduced
functional status without potential for rehabilitation is also
regarded as a relative contraindication.
Colonisation with multi- or panresistant P.a. in CF
patients does not result in inferior outcomes [27, 28]. Coloni-
sation with MRSA, multi- or panresistant Gram-negative
rods such as Stenotrophomonas maltophilia orAchromobacter
species (xylosoxidans) is also no reason to deny LTX [28].
In contrast, Burkholderia cepacia complex (Bcc) infection in
CF patients may be associated with septic clinical courses
including the so-called “cepacia syndrome” when B. ceno-
cepacia, B. multivorans, and B. dolosa are involved. The
literature reports higher mortality rates after LTX for CF
patients colonised with Bcc, especially for those colonised
with B. cenocepacia and in some reports for those colonised
with B. multivorans [29–32]. Dismal outcomes have also been
reported in patients colonised with a Gram-negative bacteria
closely related to Bcc, Burkholderia gladioli [29–33]. Many
LTX centres therefore decline patients presenting with these
pathogens (Table 2(b)). However, a case by case evaluation is
mandatory [34].
Nontuberculous mycobacteria (NTM) also pose signif-
icant challenges after LTX (see below). The prevalence of
NTM in CF patients ranges from 3 to 19% [35]. M. avium
complex (belonging to slowly growing mycobacteria) is most
common in the US, whereas M. abscessus complex (belong-
ing to rapidly growing mycobacteria) prevails in Europe.
Detection of NTM is currently not rated as an absolute
contraindication to LTX. Centers that accept patients with
Table 2: Contraindications to LTX.
(a) Absolute contraindications to LTX
(i) Malignant diseases in the past 2 years
(ii) Untreatable severe dysfunction of another important organ
system (heart, liver, and kidney) not amenable to surgical
correction/combined TX
(iii) Chronic, incurable extrapulmonary infection
(iv) Severe deformations of chest and spine
(v) Severe or symptomatic osteoporosis
(vi) Lack of adherence to therapy
(vii) Untreatable mental disorders combined with lack of
cooperation
(viii) Addictive disorder currently or during the past 6 months
(tobacco and alcohol addiction, substance abuse)
(b) Relative contraindications to LTX
(i) Age > 65 years
(ii) Critical/unstable clinical situation
(iii) Seriously limited functional status without potential for
rehabilitation
(iv) Colonisation with Burkholderia cenocepacia, Burkholderia
gladioli andMycobacteria abscessus
(v) Diseases not optimally treated (e.g., arterial hypertension,
diabetes mellitus, GERD, osteoporosis, and coronary heart
disease)
M. abscessus infection for transplantation usually advocate
aggressive treatment prior to and after LTX [36].
3.7. Preoperative Nutritional Management. Lung function
and nutrition are codependent variables in CF. Moreover,
the nutritional status has a considerable impact on muscular
function. Poor nutritional status is an independent risk factor
for poor survival in CF [37–39].
Extremes of body weight, body mass index (BMI) and
lean body mass (LBM) have been shown to negatively affect
LTX outcome [24, 40–43]. A healthy weight should be
promoted long before LTX is indicated [40]. This being said,
CF patients with end-stage lung disease are at risk of signif-
icant weight loss as energy expenditure is increased on one
hand (secondary to the increased work of breathing and the
chronic bronchopulmonary infection) and optimal calorie
uptake is compromised on the other hand (by the exocrine
pancreatic insufficiency, a loss of appetite in the context
of inflammation/infection, and the respiratory discomfort
caused by gastric distension after meals) [44–46]. Relevant
nutritional information should be exchanged between dieti-
tians from the referring CF centre and the transplant centre
to optimise management. Wait listing should not be unduly
delayed while attempts are made to correct a low BMI, as this
might result in a higher wait list mortality [9].
3.8. Psychosocial Evaluation and Support
3.8.1. Psychosocial Evaluation. The psychosocial functional
level of adolescent CF patients is compared to that of a
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normal random sample—until the disease is taking a more
serious course [47]. In adult CF patients the prevalence
of anxiety is higher whereas the prevalence of depression
is lower when compared to the general population [48].
The emotional strain is even higher for relatives, with a
third to half of the people interviewed being affected. The
pretransplantation anxiety scores are nevertheless lower in
CF patients, as they have better social support and more
functional coping strategies, than in patients, who need LTX
for other indications [49, 50].
Data on the significance of mental illnesses and on
psychosocial indicators regarding the outcome of LTX are
contradictory. Some authors suggest that mental illness is a
relative or absolute contraindication [51], others emphasise
that these disorders are relatively well treatable [52] or
request suitable support services at transplantation centres
[53]. Evaluation of LTX candidates by an external psychiatrist
is unnecessary; instead it has been advocated to involve a
psychologist, a psychiatrist, a psychosomatically experienced
physician, and/or a social worker in the care-giving team [54].
If the CF and TX centre have different locations and teams,
it is important to develop a good communication between
them in order to enable the patient’s psychosocial evaluation,
support, and integration in the new team.
There are several instruments to measure adherence and
psychosocial adjustment. An example would be the compact
Transplant EvaluationRating Scale (TERS) [55], which allows
for a structured psychosocial evaluation and enables the
examiner to assess the patient with regard to the following
domains: substance abuse, compliance, health consciousness,
social support, past coping, dealing with the current disease,
affect and mental status.
Sex and age have an additional bearing on treatment
adherence. Young female CF patients encounter significantly
more emotional tension and concern about their disease,
their degree of self-esteem is lower, they tend to be more
readily disappointed about treatment, and their adherence
in certain areas of treatment is inferior [56]. CF adolescents
feel and behave differently from CF adults. The tasks of
developing autonomy and shaping identity are radically
changed when the indication of an organ transplantation is
given [54]. The relationship with the doctor and the CF team
is considered an important factor to promote adherence in
CF patients [57].
3.8.2. Psychosocial Counselling, Therapeutic Education, and
Support Groups. Different forms of psychosocial support
intend to enhance adherence, health-related QoL, the indi-
vidual coping with illness-related anxiety, and the trans-
plantation experience.While therapeutic education promotes
active, cognitive, knowledge-based coping styles, psychoso-
cial counselling and support groups focus more on emo-
tional adaptation and integrating processes. Dealing with
regression, the transplantation experience, or a postopera-
tive delirium, it is also important to consider the patient’s
defence mechanisms and use it during post-TX counselling.
The patient’s mental representation of the donor and the
integration of the transplanted organ are seen as a positive
assimilation strategy or a disintegrative process [58].
Central topics in the counselling of CF patients prior
to LTX include patient education, enhancement of self-
efficiency, coping, and the definition of treatment objectives
and purposes in life [54]. In the postoperative period,
the desired extent of psychosocial counselling and support
remains nearly as high as pre-TX. The prevalence of anxiety
disorders is unchanged whereas depression decreases [53].
Rejection, side effects of medication, return to “normalcy,”
feelings of guilt [59], and social and legal questions are
among the primary issues for which psychosocial support
and counselling are sought. Adolescent CF LTX recipients
are also dealing with long-term goals (e.g., 80% wish to get
married and have children), interpersonal relations (peers,
feeling of belonging), and the desire to regain control over
their everyday life and their illness. Psychological help and
support for LTX patients have proved successful and have
been firmly established in a number of transplant centres
[60]. In addition, self-help organisations are increasingly
taking over important tasks of counselling and support.
4. Perioperative Approach
4.1. Bridge to Transplant. At the preterminal stage of res-
piratory failure, extended intensive care measures may
become necessary to stabilise the patient in imminently life-
threatening situations. In the event of terminal failure of gas
exchange, various temporary organ replacement options are
available as “lung replacement” after conventional ventilation
modalities have been exhausted. These extracorporeal life
support systems (ECLS) enable direct oxygenation of or
CO
2
extraction from the blood. When LTX is indicated,
these technologies (in particular interventional lung assist
(iLA), venovenous or venoarterial extracorporeal membrane
oxygenation (VV-/VA-ECMO)) may be used as a bridge to
transplant. Experienced centres report 1-year survivals of
60–92% [61–63]. These bridging modalities are resource-
intensive; they may be maintained for a limited time (a
maximum of some/several weeks). Prompt organ availability
is a prerequisite for a successful outcome in these situations.
4.2. Surgical Procedures. The surgical techniques for LTX are
nowadays similar throughout the world. Therefore, we will
not discuss well-known surgical details but will focus on
special considerations in CF patients.
4.2.1. Lung Donation and Allocation. While the vast majority
of donor lungs are retrieved from donors after brain death
(DBD), donation after circulatory death (DCD) has led to
a substantial increase in available donor organs over the
last years [64, 65]. Lungs from DCD donors have been
successfully transplanted inCF patients. Furthermore, ex vivo
lung perfusion technique (EVLP) is an emergent new option
to increase the donor pool. It allows to evaluate otherwise
unacceptable donor lungs over several hours after retrieval
and to recondition them for subsequent LTX [66–68].
Donor lung allocation is principally based on blood group
compatibility and size matching. Size matching is primarily
based on donor and recipient predicted total lung capacity
(TLC). It has to be taken into account that in CF recipients
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sometimes the real TLC can differ significantly from the
predicted TLC [69]. At present, there is no matching for
major histocompatibility antigens nor for viral (CMV, EBV)
status of donor and recipient.
4.2.2. Type of Lung Replacement. Given that a remaining
CF lung would serve as a source of infection, CF patients
generally require a bilateral LTX. The most widespread
operative technique today is bilateral sequential LTX [70].
The most widespread operative technique today is bilateral
sequential LTX [70]. In rare circumstances, where there is a
retracted and destroyed lung in one of the thoracic cavities
and a hyperdistended lung on the other side accompanied
by a fixed shift of the mediastinum, a single-lung transplant
combined with a pneumonectomy of the destroyed lung or
combined heart-lung transplantation can be indicated.
4.2.3. Operative Technique. The most common approach for
CF recipients is a bilateral anterolateral thoracotomy that
provides the best exposure to both lungs and the heart. Trans-
verse sternotomy is only performed if exposure warrants it.
Positioning of the patient is supine with abducted arms and
the chest elevated by inflatable cushions.
During pneumonectomy, in case of a previous pleurode-
sis or dense pleural adhesions, special attention has to be paid
to avoid phrenic and left recurrent laryngeal nerve injury
while mobilizing the lungs (see below). Pneumonectomy is
started with stapling of the pulmonary vessels. The bronchus
is prepared centrally and cut with a scalpel, and the lung is
removed from the chest cavity. Denudation of the recipient
bronchus beyond the level of the planned anastomosis should
be avoided by anymeans to prevent ischemia of the bronchial
anastomosis (see below); however, bulky or calcified nodes at
the recipient hilum can sometimes be a challenge during dis-
section. Any excessive lymphadenectomy should usually be
avoided to prevent significant mediastinal bleeding, though
it may sometimes be indicated to reduce infection load in
recipients infected with NTM [71].
Prior to the implantation of the donor lung, it is crucial
to achieve accurate hemostasis, since parts of the chest cavity
are difficult to access once the lung has been implanted.
In particular the posterior mediastinum can be a source of
significant bleeding in CF recipients.
Donor lung preparation is usually performed immedi-
ately prior to implantation. The bronchus is shortened with
only one cartilage ring remaining after the separation of
the upper lobe bronchus. The peribronchial tissue has to
be preserved and denudation of the bronchus has to be
avoided under all circumstances to prevent bronchial healing
complications (see below) [72].
4.2.4. Size-Reduced LTX. Given that many CF recipients
are still smaller than the average population, the waiting
time until an appropriate donor lung can be identified may
become unacceptably long. Therefore, several techniques
have been developed to accept oversized donor organs for
urgent paediatric or small adult recipients [73]. Available data
show no adverse effect of pneumoreduction on survival and
posttransplant spirometry, allowing safe use of larger donors
in small CF recipients [74, 75].
In case of a moderate size mismatch, nonanatomical seg-
mental resections are a straightforward technique to reduce
the size of the donor lung. The middle lobe and the lingula
are the preferred target areas for these resections, which are
performed immediately prior to the implantation or after the
lungs are implanted and perfused.
In case of a more significant size discrepancy, lobar trans-
plantation is another option. Some specialised centres per-
form living-related transplantation of (usually the lower) lung
lobes from two healthy relatives/donors. Living-related lobar
transplantations are exceptional procedures [76]. Split lung
transplantation is performed by subdividing the parenchyma
of a left donor lung and replacing the right recipient lung
by the donor’s upper lobe with inverse anastomosis of
the bronchus (pars cartilaginea to pars membranacea). The
recipient’s left lung is replaced by the donor’s lower lobe [73].
4.2.5. Extracorporeal Support. The routine use of intraopera-
tive ECLS in bilateral LTX is still controversial. For many CF
patients, extracorporeal support becomes necessary during
surgery, though. This is often due to insufficient oxygenation
on single-lung ventilation or hemodynamic instability, partly
because of the necessity of retracting the heart to facilitate the
exposure in the rather small chest cavities of these patients,
but especially in patients with secondary pulmonary arterial
hypertension. ECLS facilitates intraoperative cardiocircula-
tory and respiratory stability. They also protect the first
implanted lung, which is otherwise exposed to the entire
cardiac output during the transplantation of the second
lung, from the consequences of uncontrolled reperfusion,
which might result in reperfusion oedema and primary graft
dysfunction (PGD) [62].
Themostwidespread intraoperative support device is car-
diopulmonary bypass (CPB).However, an increasing number
of institutions use venoarterial ECMO with heparin-coated
cannulas instead of CPB, which avoids full heparinisation
and therefore leads to reduced blood loss. This approach can
be especially recommended for CF patients, who very often
present with dense pleural adhesions and a resulting high risk
of pleural bleeding. Intraoperative extracorporeal support
can be provided either by central or peripheral cannulation
over the femoral vessels [77].
4.3. Surgical Complications. The surgical complications
occurring in LTXmaybe evident peri- andpostoperatively up
to several months after surgery. Early complications include
hemorrhage, reperfusion injury, vascular obstructions, nerve
lesions, and wound infections. Later complications are
mostly bronchial suture healing defects.
4.3.1. Bleeding. Hemorrhages after LTX are the most com-
mon complication. CF recipients in particular tend to develop
more serious bleedings in the peri- and postoperative period
due to pleural adhesions. If chest surgeries or pleurodeses
were performed prior to LTX, the surgical risk is greatly
increased [78]. It is not unusual that patients—after a
successful LTX—have to return to the operating room in
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the immediate postoperative period for clot removal and
cleansing of the pleural spaces.
4.3.2. Reperfusion Injury. Reperfusion of the donor lung
may lead to reperfusion injury and reperfusion edema,
which may result in PGD. Clinically, PGD occurs during
the first 24 to 72 hours after LTX and mimics classical acute
respiratory distress syndrome (ARDS).The severity of PGD is
classified following ISHLT criteria [79]. Treatment is similar
toARDS.Histology usually confirms diffuse alveolar damage.
Mortality correlates with the severity of PGD and is one of
the main causes of death in the early postoperative period of
LTX [80]. Furthermore, PGD is also a hazard for bronchiolitis
obliterans syndrome and chronic graft rejection [81].
4.3.3. Vascular Complications. Surgical vascular complica-
tionsmay occur at the suture siteswith secondary obstruction
or thrombosis of the vessel. Severe and life-threatening
consequences of angio-occlusions culminate in total graft
failure or in a fulminant infarction. Immediate surgical
repair should always be the therapeutic intervention, that is,
complete thrombectomy [82, 83]. After LTX, there is also
an additional increased risk of deep vein thrombosis and
pulmonary artery embolism [84].
4.3.4. Nerve Lesions. Phrenic nerve palsy is an infrequent, but
potentially serious complication of LTX. Phrenic nerve injury
may result from traction during lung mobilisation, traumatic
dissection, thermal injury by electrocautery, or local topical
hypothermia. If bilateral, phrenic nerve palsy may require
prolonged ventilatory support either by mechanical ventila-
tion via a tracheostomy or by noninvasive ventilation. It may
recover over time [85, 86]. Recurrent laryngeal nerve palsy
may also occur and lead to vocal cord paralysis.
4.3.5. Airway Complications. The correct healing of the
bronchial sutures is a major challenge after LTX, as the
bronchial artery circulation is not reestablished and these
sutures are, thus, prone to ischemia. The healing of the
bronchial anastomoses is typically classified according to
Whitson et al. [80]. Bronchial anastomotic complications
have been significantly reduced by improved surgical tech-
niques in recent years and in most centres the reported
prevalence is <5% by now; however, wide variations are seen
as there is no standardised approach to reporting these com-
plications [87]. Bronchial anastomotic complications include
necrosis, stenosis, malacia, and dehiscence [88]. Many
cases can be managed conservatively; those which require
treatment can mostly be solved by interventional endo-
scopic procedures (e.g., high-frequency diathermia, laser
therapy, cryotherapy, balloon bronchoplasty, endobronchial
brachytherapy, and stent implantation) [89]. Repeated surgi-
cal measures such as resurgery of anastomosis, sleeve surgery,
and retransplantation are only performed in exceptional
cases.
Probably because of preservation issues some patients
develop bronchial complications at sites distinct of the
bronchial anastomoses, such as, for example, the vanishing
bronchus intermedius syndrome [90].
4.3.6. Wound Infections. Due to induction therapy and con-
secutive immune suppression, wound infections after LTX
are frequent complications. However, serious complications
that require surgical (re)intervention are rather rare (<1%)
[91]. A high index of suspicion must be maintained as these
immunosuppressed patients do not readily develop fever
or full-blown symptoms. Persisting complaints of thoracic
pain warrant evaluation for wound infection, pleural and/or
mediastinal infection as during dissection the thoracic cavity
may be contaminated.
4.4. Perioperative NutritionalManagement. In the immediate
postoperative period, maintenance of adequate nutritional
intake is a priority. Energy and protein requirements are
based on recommendations for general surgical and other
types of transplant patients as currently there is no spe-
cific data for CF [92]. Oral diet can usually resume on
postoperative day (POD) 1 or 2 if the patient has been
extubated swiftly. Oral intake should be increased as tolerated
with provision of adequate pancreatic enzyme replacement
therapy (PERT) [46, 93]. Appetite generally improves as
breathing becomes easier, bowel function normalises, and
mobility improves. However, anorexia, changes in taste,
nausea, vomiting, diarrhoea, or constipation may limit oral
intake [46]. These may be due to medical conditions, but a
number of the medications used to prevent or treat rejection
and infection, including antibiotics and antifungal drugs, can
also cause nausea, vomiting, diarrhoea, and changes in taste
and affect dietary intake. This is especially observed during
the early postoperative period when the patients receive
very complex medication regimens. Supplementary enteral
feeding should be initiated if oral intake is insufficient if the
patient is unable to commence an oral diet by POD 3-4 or
if longer-term (non)invasive ventilation is required. Patients,
equipped with a gastrostomy tube, can usually reduce the use
of enteral feed as oral intake increases and nutritional status
becomes adequate. At a distance from surgery removal of
the gastrostomy tube can be discussed between the patient,
CF team, and LTX team and assessed on an individual basis.
Ideally, the removal should only occurwhen a BMI>19 kg/m2
has been achieved and maintained for 3–6 months without
supplementary nutrition [94].
Following LTX, routine monitoring of fat soluble vitamin
levels is recommended, as supplements may have to be
reduced or discontinued. Hypervitaminosis A and E have
been reported [95, 96] even after supplementation ceased.
The etiology of this is unclear but may be due to altered
absorption, drug interactions, impaired retinol interactions,
or increased hepatic synthesis of retinol-binding protein.
Immunosuppression increases the risk of new onset
secondary diabetes, especially in the immediate postoper-
ative period or during treatment of acute rejection (AR)
with high-dose steroids. Special attention must be paid to
glucose controls at these times, especially in patients with
no previous history of diabetes and who may not easily
recognise symptoms associated with hyperglycaemia. The
immunosuppressive regimenmay also decompensate already
existing CF-related diabetes (CFRD) [93, 97, 98]. Insulin is
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usually required along with tailored nutritional management
to optimise blood glucose control.
Gastrointestinal complications are common post-LTX.
In the early postoperative period, constipation and distal
intestinal obstruction syndrome (DIOS) are common, partic-
ularly among patients with a history of DIOS, previous major
abdominal surgery, or meconium ileus in infancy [99, 100].
Since DIOS is associated with severe complications such
as perforation and sepsis, some centers recommend pre-op
bowel preparation in all CF patients. Counselling on adequate
fluid and dietary fiber intake should be provided and bowel
movements should occur within the first 48–72 hours after
surgery otherwise laxatives/enemas should be administered.
Clostridium difficile colonisation or recurrent infection is
common in older CF patients and diarrhoea posttransplant
should immediately trigger stool cultures and empirical
treatment until stool culture results become available as
Clostridium colitis in the setting of immunosuppression may
be devastating.
The risk of osteoporosis, which is generally higher as
a result of the underlying disease, is additionally increased
post-LTX. Pathogenesis is multifactorial, with long-term
use of corticosteroids and the calcineurin inhibitors (CNIs)
(tacrolimus or cyclosporine A) as contributing factors [4].
Adequate calcium and vitamin D intake should be encour-
aged alongwithweight-bearing exercise and antibone resorp-
tive medication as required.
5. Postoperative Care
5.1. Long-Term Follow-Up after LTX. After LTX problems
arising from the genetic disorder continue to require CF
specialist input, but specific posttransplant aspects have to
be dealt with as well. Sometimes the CF-specific topics are
predominant; at other times the posttransplant management
issues aremore acute. CF LTX recipients should ideally be fol-
lowed in an institution where CF and LTX centre are closely
cooperating and located in near vicinity in order to receive
the best possible support with respect to both conditions. In
most situations the transplant team will take the lead and the
CF team will support this management. In real life, though,
many CF patients have to travel a long way for LTX and
consequently for posttransplant care aremore frequently seen
in their CF centres or by their general practitioners (GP).
Irrespective of the model of shared care, there has to be close
contact between all actors involved in post-LTX care and
management. Accurate agreements about the tasks, functions
of control, and coordination to be taken over by either the
LTX centre or the CF centre, and/or the GP are required in
the long run [101].The patient’s GP can become an important
actor as he is often the first contact in case of problems and,
thus, should always be informed about the patient’s current
status. He may also assume the task of reviewing lab tests
and drug levels. However, the role of the GP in specific
posttransplant care varies between countries, even in Europe.
All team members involved in post-TX CF care share
the responsibility to detect signs of patient deterioration and
post-TX complications as early as possible (e.g., malaise,
fever, sputum production, dyspnea, decrease in lung func-
tion, diarrhoea, etc.).
As a general rule, any new respiratory symptom or
sign in the immunosuppressed CF LTX recipients requires
immediate attention and contact with the transplant centre.
For a CF patient, who has lived with a limited lung function
for years and who has had a successful LTX, this might
not make immediate sense; however, after a successful LTX
it is expected that the patient is free of respiratory symp-
toms and furthermore the immunosuppressionmay partially
mask symptoms/signs so that even minor respiratory symp-
toms/signs might point to a serious problem.
New digestive problems, especially vomiting and diar-
rhoea, may compromise the absorption of immunosuppres-
sive medications and, thus, expose the patient to a risk of
AR and/or have a negative impact on renal function. As a
consequence this type of symptoms should be taken seriously
as well.
Certain viral infections, such as CMV, EBV, and varicella,
can be life-threatening for transplanted CF patients [102].
Apart from LTX-related complications, CF LTX recipi-
ents are at risk for disease-specific complications that may
have a significant impact on their long-term outcome. The
risk of developing CFRD is markedly increased [97, 103, 104].
Considerable evidence demonstrates a relationship
between gastroesophageal reflux disease (GERD) and
bronchiolitis obliterans syndrome (BOS) [105].
Markers of aspiration-induced injury may be studied in
BAL or induced sputum. Acid neutralisation by adminis-
tering proton pump inhibitors seems to be insufficient to
protect against aspiration injury [106]. In contrast, surgical
therapy by fundoplication is associated with decreased levels
ofmarkers of aspiration in BAL as well as a reduced incidence
of BOS or improvements in lung function in patients already
diagnosed with BOS [107]. CF LTX recipients have an
even significantly higher prevalence (90%) of GERD when
compared to other LTX recipients suggesting that CF patients
in particular should be routinely screened for GERD after
transplantation to identify those who may benefit from
antireflux surgery [108].
The risk of osteoporosis is further increased after LTX
due to the long-term administration of corticosteroids and
CNIs [4]. Close follow-up on the bacterial spectrum in
the airways is indispensable as chronic infections with CF-
specific pathogens can persist in the upper airways and
reinfect the transplanted lung.
5.2. Immunosuppression. LTX recipients are usually on a
triple immunosuppressive therapy combining a CNI (tacroli-
mus (tac) or cyclosporine A (CsA)), an antiproliferative agent
(mycophenolate mofetil (MMF), mycophenolate sodium
(MPS), or azathioprine (aza)), and glucocorticoids (Table 3).
The immunosuppressive therapy is usually steered by the LTX
centre, but monitoring is usually provided by the GP and the
CF centre as well. The target levels of immunosuppressive
drugs depend on the time elapsed since LTX and associated
comorbidities (Table 4). An individual drug target level for
each patient should be determined in short intervals and
communicated to each care team member (LTX centre, GP
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Table 3: Typical baseline immunosuppression beyond one year after
lung transplantation∗.
Therapy Dosing
Prednisone/prednisolone 5mg daily
Mycophenolate mofetil
or
mycophenolic acid
500–1500mg twice daily
360–720mg twice daily
Cyclosporin A
or
tacrolimus
Targeting blood level of 150–200 ng/mL
Targeting blood level 8–10 ng/mL
∗Please note that patient-specific dosages have to be taken into account.
Table 4: Cyclosporin and Tacrolimus can be monitored by trough
levels.
Posttransplant
period
Cyclosporin A
(ng/mL)∗#
Tacrolimus
(ng/mL)∗#
0–2 weeks 300–350 10–15
3–8 weeks 250–300 10–15
2-3 month 200–250 10–15
3–6 month 190–250 10–15
6–12 month 150–200 5–10
>1 year 150–200 5–10
∗Please note that reference values for drug levels are given as guidance only
and may vary between centers. Patient-specific drug levels have to be taken
into account.
#In some centres postdose levels are monitored. Specific reference values are
necessary.
and CF centre). Decisions of the LTX centre to wean patients
down to a low steroid dose will be based on considerations
of individual parameters including acute rejection (AR)
episodes, the degree of renal dysfunction, and side effects.
5.3. Acute Rejection. The incidence of AR of the transplanted
lung is high for several reasons, themost important being that
there is no possibility for HLA matching. As a consequence
most LTX recipients receive completely mismatched grafts
[109].
Data from the ISHLT Registry indicate that approxi-
mately 35% of patients experience at least one AR episode
during the first year after being discharged from the hos-
pital [110, 111]. Apart from the obvious immunological risk
factors, any inflammatory/infectious damage to the lung
allograft probably increases the risk forAR. For example, viral
infections—such as community-acquired respiratory viral
infection or CMV infection—have been associated with an
increased risk of AR [112].
The clinical picture of AR is unspecific. The complete
picture of dyspnea, fever, pleuritic pain, and effusion is
only observed in the immediate postoperative period. A
drop of paO
2
or FEV
1
may provide hints. The chest CT
scan may show air trapping, septal thickening, ground glass
densities, bronchial dilatation, bronchial wall thickening,
and centrilobular opacities, but these findings are altogether
nonspecific and, most importantly, are unable to differentiate
AR from infection [113].
The gold standard for the diagnosis of AR is lung
histology based on transbronchial biopsies (TBBs). TBBs are
assessed for acute cellular vascular and bronchiolar rejection.
The severity of these processes is graded according to the
ISHLT classification [100]. The A grades define vascular
rejection according to the severity of perivascular and inter-
stitial mononuclear infiltrates (A0 to A4). The B grades
stage synchronous bronchiolar rejection according to the
severity of lymphocytic infiltration within the bronchiolar
walls (B0 to B2R) [114]. Histological interpretation of TBBs
is not always straightforward; there may be considerable
interexaminer variability.
The vast majority of LTX centres will give treatment for
AR graded ≥A2. Opinions differ regarding the indication for
treatment in case of A1 rejection. Standard therapy consists
of intravenous high-dose pulse steroid therapy (e.g., 500–
1000mgmethylprednisolone daily for 3 days). Other options,
mainly for recurrent or persistent AR, include antithymocyte
globulin (ATG), alemtuzumab (anti-CD52), extracorporeal
photopheresis, and anti-IL2 receptor antagonists.
While the existence of antibody-mediated rejection
(AMR) after LTX is at present acknowledged, its diagnosis
carries many pitfalls. When a diagnosis of AMR can be
established, specific treatments such as high-dose steroids
combined to plasmapheresis and intravenous immunoglobu-
lins and, possibly, rituximab, bortezomib, or eculizumabmay
be considered though not evidence based.
5.4. Chronic Lung Allograft Dysfunction (CLAD). Chronic
lung allograft dysfunction (CLAD), especially bronchiolitis
obliterans (BO), remains the major medium- and long-term
problem in LTX and the leading cause of death.
BO is characterised clinically by progressive shortness
of breath accompanied by a progressive and irreversible
obstructive spirometric defect. The histological hallmark
of this entity is obliteration of terminal bronchioles and
evidence of aberrant remodeling in the airway epithelium,
vasculature, stroma, and lymphoid system. BO is, initially at
least, a heterogeneous process and histological diagnosis is
difficult as TBBs are prone to sampling errors [115].
For this reason, a functional corollary, bronchiolitis oblit-
erans syndrome (BOS), has been devised by the ISHLT. After
LTX, the 2 best measurements of vital capacity (VC), FEV
1
and FEF
25–75 (obtained at least 3 weeks apart), are computed
and averaged on a regular basis. At each consultation the
patient’s lung function parameters are compared to these best
values. A chronic decline in lung functionwith an obstructive
pattern and without any identifiable cause (such as AR,
bronchial anastomotic complications, bronchopulmonary
infections, phrenic nerve palsy, and pleural effusions) is, then,
graded according to the ISHLT BOS classification. There
are 5 stages: BOS 0 (no decline in lung function), BOS 0-p
(potential BOS), and BOS 1–3 [116].
The clinical presentation of BO/BOS is very hetero-
geneous. The type of presentation, the time from trans-
plantation to onset, and the rate of progression are all
very variable. BO/BOS may present as an acute illness and
imitate a respiratory infection, but very often it is at first
an asymptomatic process revealed by an insidious decline in
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lung function. In aminority of patients BO/BOSmay develop
within 2 years of LTX (early-onset BOS); however, the vast
majority of affected patients develop the complication at a
later time-point. The rate of decline in lung function is also
very variable: in some patients the decline is very rapid, in
others a slow decline over years is observed. Older reports
indicate that survival 5 years after LTX is 20–40% lower
in patients, who had a diagnosis of BO/BOS compared to
patients free from BO/BOS [117]. However, these data have
potentially evolved and series, which have not differentiated
BO/BOS from other conditions such as, for example, RAS
(see below), probably overestimate BO/BOS mortality rates.
Of note, however, early-onset BO/BOS (within 2 years) shows
a worse prognosis than does late-onset BO/BOS.
Known risk factors for BO/BOS are recurrent episodes of
AR, the development of anti-HLA antibodies, but also bacte-
rial/fungal colonisation of the graft (P. aeruginosa recoloni-
sation of the lung transplant is considered an independent
risk factor for the development of CLAD [118]), community-
acquired respiratory viral infection, CMV pneumonitis and
GERD.
Prevention of BO/BOS includes addressing all known
risk factors. This is the reason why at least 50% of LTX
programs perform surveillance TBBs during at least the 1st
year after surgery. The development of donor-specific HLA
antibodies should probably also be followed prospectively,
even if at present there would be no specific therapy protocol
in patients becoming antibody positive.
There is no current effective therapy for BO/BOS. Once
the diagnosis is established, a change of immunosuppres-
sive therapy is often operated, most frequently to no avail.
However, overimmunosuppression should be avoided in
order not to trigger infectious events. A 3–6-month course
of azithromycin is justified. GERD should be reevaluated
and treated aggressively. All infectious episodes should be
treated promptly. General supportivemeasures such asmain-
taining a correct nutritional status are important. In some
circumstances, photopheresis or total lymphoid irradiation
is proposed and able to stabilize lung function. In selected
patients redo-LTX can be carried out.
In addition to representing a major obstacle to long-term
survival, BOS also causes significant morbidity and loss of
health-related QoL [119].
Historically, it has been believed that BO/BOS is the
equivalent of “chronic rejection.”However, the understanding
of chronic lung allograft dysfunction is continuously evolving
and the term “chronic rejection” is currently intention-
ally avoided by many LTX specialists for several reasons
(although “chronic rejection” is still an expression used by
many patients and caregivers) [120]. First of all, it has become
clear that alloimmune, nonalloimmune, and even autoim-
mune factors contribute to the development of BO/BOS; thus,
BO/BOS might be the final expression of ANY aggression
to the lung allograft. Secondly, there are potentially several
subtypes of BO/BOS. A subpopulation of BO/BOS patients
show airway neutrophilia and seem to respond relatively well
to azithromycin (neutrophilic reversible airways disease).
Another subpopulation of BO/BOS patients do not present
with airway neutrophilia, tend to showmainly airway fibrosis
with less inflammation, and are believed to be unresponsive
to azithromycin. Finally, recently, it has been recognised that
there are still other types of lung disorders, for example,
the recently described restrictive allograft syndrome (RAS),
which contribute to the respiratory morbidity and mortality
after LTX [121]. RAS is characterised by restrictive ventilatory
defect, infiltrates on lung CT, and peripheral foci of inflam-
mation and fibrosis. In general, RAS shows poorer survival
than BO/BOS. For all these reasons, the term chronic lung
allograft dysfunction (CLAD) has been coined in order to
include all these entities.
5.5. Infections in the Context of Immune Suppression. LTX
recipients have a higher risk of infectious complications
than recipients of other solid organs because of the constant
exposure of the lungs to the environment, altered cough
mechanism, bronchial circulation, lymphatic drainage, and
the intensity of immunosuppression, which induces a state of
persistent T- and B-cell dysfunction.
Infections (particularly pulmonary infections) are a fre-
quent complication after LTX and constitute the major cause
of patient morbidity and mortality [122]. Respiratory tract
infections are the most common type of infection after
LTX, with bacterial pneumonias being the leading cause in
this category. CMV is the second most common infection
followed by fungal and mycobacterial infections.
A timetable of infections—dividing the post-LTX era into
3 periods—can be established (Table 5). This categorisation
is not absolute and infections may be distributed among
alternative periods, particularly depending on underlying
prophylactic and immune suppressive regimes [123].
In the early period (1st postoperative month) nosocomial
infections due to bacteria and yeasts that might be observed
in other surgical patients and infections due to classical CF
pathogens are most frequent.
CF-specific pathogens persist in the paranasal sinuses
and upper airways and may cause infectious episodes. As
stated abovemany LTX centres refute CF patients harbouring
Bcc, notably B. cenocepacia and B. gladioli because these
pathogens are prone to cause immediate invasive disease with
pneumonia, empyema, septicaemia, and death. Favourable
long-term results in B. cenocepacia-positive patients are only
reported in individual cases [124]. B. gladioli, moreover, may
cause skin or soft tissue infections (i.e., sternum, chest wall,
and mediastinum) as well as sepsis [124, 125]. The survival
forB. gladioli-positive patients after LTX is significantly lower
than for patients with or without Bcc (with the exception
of B. cenocepacia) [32, 126]. The reported incidence of
NTM infection post-LTX is variable. Pulmonary infiltrations
and/or infections of skin and soft tissue (e.g., sternal abscess,
mediastinitis) predominate.
CF LTX recipients may suffer from nosocomial infec-
tion, including respiratory tract, urinary tract, skin and
soft tissue, and catheter infections, or septic courses dur-
ing hospitalisation. Respiratory tract and catheter-related
infections are the major cause for bacteremia or sepsis. The
immune suppression (induction therapy), “medical devices,”
and the administration of broad-spectrum antibiotics (typ-
ically selected to cover a patient’s individual spectrum of
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Table 5: Timetable of infections following LTX.
1st month 2nd–6th month >6 months
Nosocomial infections∗
Respiratory tract infections
Surgical site infections
Urinary tract infections
Catheter infection, sepsis
Reactivation of latent
infections + opportunistic
infections
Community-acquired
infections/pneumonia
Related more to surgery and
intensive care Related more to immunosuppression
CF lung pathogens:
Pseudomonas spp.
Burkholderia cepacia complex
B. gladioli; NTM
Other bacteria:
S. aureus
Enterobacteriaceae
Enterococci
Acinetobacter spp.
Fungi:
Candida spp.
(Aspergillus spp.)
Viruses:
Herpes simplex virus
Respiratory viruses
Viruses:
Cytomegalovirus
Epstein-Barr virus
Herpes simplex virus
Varicella Zoster virus
Opportunists:
P. jirovecii
Toxoplasmosis
Aspergillus spp.
Nocardia
Listeria
Mycobacteria
(especially NTM)
CF-lung pathogens:
Pseudomonas spp.
Burkholderia spp.
Viruses:
Epstein-Barr virus
Respiratory viruses
Respiratory bacteria:
S. pneumonia
H.influenzae
C. pneumoniae
M. pneumoniae
and others
CF lung pathogens:
Pseudomonas spp.
Burkholderia spp.
Fungi:
Aspergillus spp.
C. difficile infection∗∗ Late-onset C. difficileinfection
∗May occur also in later periods after LTX depending on prolonged or recurrent hospitalisation and the presence of medical devices.
∗∗Highest incidence within the first 3 up to 12 months after LTX in association with broad antimicrobial therapy and intense immunosuppression.
CF pathogens and their resistance phenotypes prior to
transplantation) are major risk factors. Thus, the relevant
pathogens comprise frequent nosocomial Gram-positive and
Gram-negative bacteria such as S. aureus (MRSA/MSSA),
Enterococci, Enterobacteriaceae (e.g., E. coli, Klebsiella spp.,
Enterobacter spp., etc.), P. aeruginosa, Acinetobacter spp., and
mainly Candida spp. [126–129].
In the middle period (2–6months after surgery) immuno-
suppression is maximal and this may in particular trigger
reactivation of latent pathogens that were present in the lung
donor or in the LTX recipient before surgery. Consequently,
infections due to immunomodulating viruses (CMV, EBV,
human herpesvirus 6, and hepatitis B andC) and opportunis-
tic infections (by pathogens such asAspergillus spp., Pneumo-
cystis jirovecii, and Listeria monocytogenes) predominate.
Cytomegalovirus (CMV) belongs to the herpes virus
family and, after bacterial pneumonia, constitutes the second
most common cause of infection in LTX recipients [130].
The risk of CMV infection is related to the recipient’s pre-
transplant serological status, degree of immunosuppression,
and type of antiviral prophylaxis during the early transplant
period.
While short-term mortality in acute CMV infection has
been reduced by CMV-killing virustatic agents, the indirect
immunological effects of CMV infection predispose toCLAD
[131].
CMV infectionmust be differentiated fromCMVdisease.
CMV infection is characterised by an asymptomatic state
of virus replication on clinical chemistry, whereas CMV
disease signifies virus replication, clinical symptoms (e.g.,
fever, myalgias, and arthralgias), and tissue-invasive end
organ involvement. After LTX, CMV pneumonitis is the pre-
dominant manifestation of CMV disease, but CMV hepatitis,
gastroenteritis, or colitis is also encountered. CMV retinitis is
less frequent than in AIDS patients [132].
Serologic tests (CMV antigen pp65), quantitative and
qualitative PCR examination (CMV-DNA-PCR) of blood and
BAL fluids or tissue samples [133], are used to establish the
diagnosis. Histopathology is the gold standard of diagnosis
of CMV disease. Prophylactic or preemptive treatment of
CMV is recommended between 3 and 12 months after
LTX depending on donor-recipientmatching, CMV-negative
recipients of CMV-positive donor lungs being at the highest
risk of developing disease.
Due to a high risk of CLAD, it is advisable to treat LTX
patients already when diagnosed with asymptomatic CMV
viremia [133].
The spectrum of Aspergillus-related infections ranges
from simple colonisation to invasive tracheobronchitis to
invasive pulmonary or disseminated aspergillosis [134].
Invasive tracheobronchitis is particularly dangerous
in the early postoperative period when it may affect
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the bronchial suture, compromising its healing with—
sometimes—disastrous effects such as fistula formation
between bronchus and adjacent pulmonary artery [135].
Invasive pulmonary and disseminated forms are seen mostly
later on [136, 137]. Risk factors for invasive aspergillosis
include colonisation prior to LTX, extensive ischemia and
necrosis of the bronchial anastomoses, CMV infection,
high-dose steroid therapy, and increased maintenance
immunosuppression in the context of CLAD.
Preventive management is carried out up to six months
after LTX or at times of increased immunosuppression;
there are no standardised protocols, but individually targeted
approaches have been described [138].
Before the discovery of the novel triazole-antimycotics
(e.g., voriconazole, posaconazole) invasive pulmonary or
disseminated aspergillosis in a LTX recipient was uniformly
fatal; these drugs are nowadays the treatment of choice and
allow for a better prognostic outlook [139].When prescribing
these drugs particular attention should be paid for inter-
actions with CNIs (CNI metabolism is inhibited by azoles
and, thus, blood levels increase significantly) and other drugs
metabolised via theCYP3A4 enzyme cascade. Echinocandins
or lipid formulations of amphotericin B are potential, but less
effective, substitutes [137].
All solid organ transplant recipients are at a high risk
for Pneumocystis jirovecii (Pj) pneumonia, especially in the
first posttransplant year. This pathogen may lead to a life-
threatening interstitial pneumonia. Continuous prophylactic
administration of trimethoprim/sulfamethoxazole on 3 days
of the week has very significantly reduced the incidence
of Pj pneumonia after LTX, which nowadays is very rare.
Pneumocystis and/or trophozoites are visualised in BAL by
Grocott’s or Giemsa’s staining; PCR-based methods are also
available to ascertain the diagnosis of Pj pneumonia. High-
dose trimethoprim/sulfamethoxazole is the treatment of
choice; concomitant steroid therapy is required if the patient
is hypoxemic [140]. Side effects are common, particularly at
the high doses of trimethoprim/sulfamethoxazole used in
therapy (severe rash, associated with fever, cytopenia, and
deterioration of kidney function). Alternatives, but less effec-
tive, are nebulised pentamidine, oral dapsone, or atovaquone
suspension.
C. difficile is isolated from stool specimens in 30–50% of
CF patients, considerably more often than in other patient
groups. In the first year after LTX, CF patients are 2-3
times more susceptible to C. difficile-associated diarrhoea
and colitis than non-CF patients [141]. Severe colitis is a rare
but classical cause of death in CF LTX recipients [142, 143].
C. difficile infection, however, may establish also after years
mostly in the context of intensified immunosuppression due
to graft rejection [144].
5.5.1. Respiratory Syncytial Virus Infection. RSV infection
after LTX has prevalence of up to 20% and, along with acute
morbidity, is an independent risk factor for the development
of CLAD. Diagnosis is made by detection of virus replication
(RSV-DNA-PCR) in nasopharyngeal specimens. Treatment
is primarily carried out with ribavirin (if available) or an
increased dose of steroids [145].
Onset in the late period is mainly associated with
increased immune suppression in the context of CLAD.
5.6. Malignancies and Lymphoproliferative Diseases. Solid
organ TX, independent of the underlying disease, increases
the risk of malignancy by three- to four-fold. After LTX, the
Registry of the ISHLT reports that 28% of ten-year survivors
developed a malignant disease [146]. The risk of malignancy
increases with time. In CF LTX recipients the risk of cancer is
about six times higher than in the general population, with a
substantial incidence of tumours involving the gastrointesti-
nal tract (21-fold), skin and lymphoproliferative diseases (44-
fold) [147].There are no specific guidelines for the prevention
of malignant disease after LTX. It is recommended to follow
at least the guidelines for the general population. Addi-
tionally, consistent application of sunscreen, avoidance of
overexposure to sunlight, and regular dermatological checks
are advised to prevent skin tumours. Regular screening
colonoscopies, probably to be started at an earlier age than
in the general population, may identify premalignant colonic
lesions and prevent progression to malignancy [148].
5.6.1. Posttransplantation Lymphoproliferative Disease
(PTLD). PTLD denotes various lymphoproliferative diseases
(including lymphomas) occurring after TX and affecting 2–
8% of the adult transplant recipients. PTLD occurs typically
in the context of Epstein-Barr virus (EBV) infection or
reactivation, which leads to immortalisation of EBV-infected
B cells. Immunosuppression after TX inhibits T cell-mediated
control of these cells leading to lymphoproliferation.
The risk for PTLD is particularly high in EBV-
seronegative recipients of EBV sero-positive donor lungs
(∼30% compared to <5% in sero-positive LTX recipients),
which also explains the even higher risk for transplanted
children. Other risk factors include the type of induction
therapy and the intensity of immunosuppression. PTLD
can be asymptomatic in the early stages and symptoms may
remain nonspecific thereafter. Imaging studies are performed
according to the patients’ complaints, definite diagnosis is
made by histology, and the disease is categorised according
to WHO recommendations [149].
Clinically, two different courses of PTLD can be dis-
tinguished. Early PTLD is observed during the first year
after LTX, with frequent intrathoracic manifestations and a
mostly polyclonal histology. Delayed PTLD appears later and
often outside the allograft and tends to be EBV negative. Its
prognosis is poorer. The most important treatment options
for PTLD include reduction of immune suppression (if pos-
sible), administration of an anti-CD20 antibody (rituximab)
(if the PTLD is a B cell disease), and/or chemotherapy [150].
Rescue therapies consist of autologous/allogenic stem cell
transplantations.
6. Other Topics
6.1. Physiotherapy Intervention. Physiotherapy before and
following LTX includes respiratory management, physical
and functional rehabilitation, and education. Short-term and
long-term goals need to be set.
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The goal of intensified physiotherapy prior to LTX is to
maintain the waitlisted patient in a clinically optimal condi-
tion for surgery. Apart from improving chest mobility and
airway clearance, an individually tailored exercise program
to improve functional capacity is usually started. Such a pro-
gram may include aerobic conditioning as well as exercises
to increase strength, flexibility, and/or balance/coordination.
After LTX themain goal is to lessen chest pain and discomfort
caused by the clamshell incision, improve breathing and
cough while improving physical fitness as quickly as possible
to avoid immobilisation, and to allow the patient to perform
everyday activities [151].
6.1.1. Types of Physical Training. Physical training is defined
as participation in a program of regular vigorous activity
designed to improve physical performance or cardiovascular
function or muscle strength or any combination of these
three [152]. In general, people with CF can benefit from
a wide range of different training modalities, for example,
aerobic, anaerobic, and strength-training. Short- and long-
term aerobic and/or anaerobic training have been proven to
result in positive effects on lung function, aerobic fitness,
strength, and quality of life [153–155].
In people with severely impaired pulmonary function
and muscle wasting, interval training or moderate strength
training might be better tolerated than continuous aerobic
exercises. Although the evidence is sparse, support by oxy-
gen supplementation [156] and noninvasive ventilation may
allow/facilitate physical training in patients with severely
altered respiratory function.
Aerobic training may include cycling or walking for a
prescribed length of time at a targeted intensity, or interval
training. Often, aerobic training intensity is based on a
standardised exercise test. Some rehab facilities use the steep
ramp test originally developed for cardiac rehabilitation [157]
to guide interval training.This approach has been adopted for
rehab in pulmonary diseases [158] and also used successfully
in CF patients before and after LTX [159].
Although the data on severely ill patients is limited, clini-
cal experience shows that supervised strength training is fea-
sible and safe and sometimes better tolerated than endurance
type exercises. Sufficient time for recovery, that is, more than
48 hours, is required following an intense training session.
6.1.2. Before TX. Standardised exercise testing is routinely
used in the pretransplant assessment [160–162]. Currently,
most centres employ the 6-minute walk test [161]. However,
other exercise tests, including full cardiopulmonary exercise
testing, are also used andmay provide additional information
[161, 162]. Besides providing prognostic information [160,
162], the exercise test can guide advice on exercise training
and conditioning during the waiting period and during
posttransplant rehabilitation.
Preoperative rehabilitation aims to achieve optimum
conditioning with regard to strength, endurance, mobility in
everyday life and nutritional condition, at creating a better
starting point for the transplantation thereby making for a
better postoperative outcome [163].
The poorer a patient’s condition is, the more he/she
is going to benefit from an individually adjusted training
program [164]. Preoperative rehabilitation may furthermore
add to the selection of appropriate candidates or to the
determination of the listing point. Contraindications for
LTX—which previously were gone unnoticed—may become
obvious during rehab. Inmany cases prior to LTX,CFpatients
do notmeet the defined criteria for rehabilitation. Cardiopul-
monary performance is frequently restricted to the extent
of immobility, and the patients are incapable of taking care
of themselves. Pulmonary rehabilitation must be oriented
along the individual limitations and capacities of the LTX
candidates, and this can only be done in specialised centres.
Disease-specific features have to be taken into account, for
example, bacterial colonisation in CF patients.
Besides the inhalation treatment and airway clearance
sessions, patients should have access to exercise training three
times a week in order to ensure that they are in an optimal
condition for surgery. The individualised programme needs
to be regularly reviewed by an expert physiotherapist or
exercise specialist and regular assessments are required to
adjust the programme to possible improvements in fitness or
deterioration of general health.
6.1.3. After TX. Physiotherapy programs should be initiated
in the ICU setting. Early mobilisation and daily physiother-
apy is essential [165], taking into account the individual limi-
tations of performance.The benefits of postoperative rehabil-
itation after LTX include reduced dyspnoea and subjectively
an improved general condition [166]. A clinically relevant
improvement of the walking distance (6-minute walk test)
[167] and improvedQoL after LTX [168] can be accomplished
by individualised endurance and strength training.
Physiotherapy and respiratory therapy play a key role
for patients with CF even after the transplantation. Aside
from improving the elimination of secretions in the early
postoperative period, it is essential to counteract limited
ventilation due to thoracic restriction and pain related to
scars/contractures. Conditioned pathologic breathing pat-
terns must be compensated by correcting the patients’ res-
piratory perception. This is also paramount since perception
in the transplanted organ had been reduced by surgical
denervation [169, 170].
After successful transplantation, physiotherapy must be
continued past the period of early rehabilitation. Patients
falsely overestimate their performance after LTX [166]. Con-
tinued resistance workouts are important to counterbalance
the effects of long-term steroid intake.
6.2. Other Solid Organ Transplantations in CF (Heart, Liver,
Kidney, and Pancreas). Heart-lung transplant is a major
procedure that carries a high risk of complications. It is
rarely performed in CF at present due to the fact that after
bilateral lung transplantationmyocardial recovery from right
heart failure is dramatic and obviates the need for cardiac
replacement [171].
The occurrence of liver disease in CF (CFLD) is specified
at 27–35% by age of 18 years [172]. Incidence is at 2.5 per 100
patient years in the first ten years of life, with a prominent
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decline in the second decade. 5–10% of all patients will
develop multilobular cirrhosis [173]. Liver transplantation
(LiTX) is the treatment of choice in advanced CFLD. The
indication for this procedure in CF differs compared to other
diseases with chronic hepatic failure. Extrahepatic factors
have to be considered as well, for example, progressive deteri-
oration of nutritional condition (catabolism) and particularly
pulmonary factors such as deteriorated lung function and
an increased number of pulmonary exacerbations. Paediatric
patients will benefit from early LiTX with improved lung
function, since pulmonary alterations are more likely to be
reversible in them than in adults. Given that particularly in
CF disease severity and urgency of transplantation cannot be
defined by common scoring systems like MELD (model of
end-stage liver disease) or PELD score for paediatric patients
[174], CF was added to the group of “standard exceptions”
(exceptional and match-MELD score) to facilitate a better
allocation of donor organs and improve the chance of a timely
transplantation. Indication is clear in case of progressive
hepatic dysfunction, uncontrollable ascites and variceal hem-
orrhages, hepatopulmonary syndrome, severe malnutrition.
reduced QoL, and declining lung function due to advancing
decompensation. A typical contraindication is poor pul-
monary function. The threshold value for LiTX alone has
been set empirically rather than evidence based at FEV
1
/FVC
<50% [175–177]. In any case, LiTX should be performed
before lung function declines significantly. Immunosuppres-
sive therapy does not differ here from other LiTX patients;
however, CF patients show fluctuating drug levels more
frequently and may require closer monitoring. CF patients
develop diabetes mellitus more frequently than others after
LiTX, whereas the prevalence of reduced renal function at
2 and 5 years is similar to that of LiTX recipients without
CF [177]. CFLD treatment and liver transplantation have a
positive effect on lung function in both children and adults;
the long-term course of lung function is not truly influenced
by LiTX, though, and matches that of patients without CFLD
[178]. Inversely, CFLD does not constitute a contraindication
to planned LTX, provided that hepatocellular function is
conserved and portal hypertension is controlled [179].
In rare cases combined liver and lung transplantation has
been performed, but the risk of perioperative complications is
high and larger series are not available [180, 181]. In one small
series the overall survival of those receiving a combined liver
and lung transplantationwas 70% at one and three years [181].
In rare instances a CF patient requires combined or
sequential lung and kidney transplantation [182]. There are
some reports on transplantations of pancreas, simultaneous
liver-pancreas, or lung-pancreas [183, 184].
However, a recent meta-analysis of abdominal organ
transplantation in CF concludes that pancreatic transplanta-
tion in CF is not an established procedure [185].
6.3. Pregnancy after Lung Transplantation. Successful preg-
nancy is possible after lung transplant, even among recipients
with a diagnosis of cystic fibrosis [186]. However, these
pregnancies are high-risk and require close maternal and
fetal surveillance through coordinated care among maternal-
fetal medicine specialists and transplant personnel. Little
is known about how the profound immunologic changes
associated with pregnancy influence tolerance or rejection
of the allograft and lung recipients appear at greatest risk
for poorer pregnancy outcomes. Recipients should be in
general good health and there should be optimal control
of comorbid conditions such as liver function and diabetes
prior to conception. Graft function should be stable and
rejection-free. During pregnancy, maintenance-medication
regimens should be continued with vigilant monitoring for
effective drug levels and drug side effects with appropriate
dose adjustment. Transplant professionals have to be aware
of any additional risk to the fetus from immunosuppressive
medications relative to the potential improvement in mater-
nal graft function/survival conferred by each of these agents
(e.g., mycophenolic acid is associated with a 23% incidence of
birth defects) [187].
With the constant advent of new developments and
modifications in immunosuppressive regimens, clinicians are
responsible for providing pregnancy counselling to all pre-
and posttransplant recipients of childbearing age. Caregivers
have to be aware of how they relay the data and appreciate
how recipients will process this information in order to make
an informed decision regarding parenthood after transplan-
tation, even in the face of potential risks. Ultimately, the
patient has to be given the opportunity to make the decision
[188].
6.4. Patient Education and Learning Objectives after LTX.
After lung transplantation, CF patients have to acquire a lot of
new skills to manage their life with a new chronic condition:
adjust to new therapy, nutrition, and care regimens; manage
new medications and risks; and control new emergency sit-
uations like rejection and infection. Multidisciplinary trans-
plant teams should offer structured patient-centred education
programs,with training sessions ensuring that the patientwill
be able to effectively manage unpredictable situations, espe-
cially those jeopardizing the outcome of the graft. Education
can be facilitated by visual aids and written booklets.
Some learning objectives are crucial and should be
acquired between the time of transplant and the first return
home (Table 6) [189, 190]. Detailed explanations should
be provided as to the mechanism of action/absorption of
immunosuppressive drugs and their anticipated side effects,
the need for prophylactic anti-infectious therapy, and drug-
drug and drug-food interactions. Patients with CFRD should
receive ongoing diabetes self-management education, and
education about the symptoms, prevention, and treatment of
hypoglycemia is recommended for patients with CFRD and
their care partners [191].
Other learning objectives should be addressed in the
rehabilitation clinic and during the post-LTX outpatient
visits, tailored to the patient situation and needs (e.g., impor-
tance of hydration and quantity of dietary salt, environmental
risk factors, use of contraception, and prevention of sexually
transmitted diseases, etc.) [192]. The use of knowledge ques-
tionnaires and other tools like clinical cases and scenarios
facilitates the achievement of these objectives.
Finally, attention should be given to socioeconomic con-
ditions and regular meetings with the social worker should
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Table 6: Learning objectives for the time between LTX and first
return home.
(i) Identify warning signs of a change in respiratory status
(including results of spirometry/PFT)
(ii) Respond to warning signs of a change in respiratory status
(iii) Describe the vital nature of immunosuppressants (role, mode
of action, lifelong therapy, importance of biological monitoring)
(iv) Comply with proper handling of immunosuppressants
(v) State the role and mode of action of other medications
(vi) Respond to forgetting a medicine or to vomiting
(vii) Manage the stock of drugs and equipment
(viii) Identify food-related risks
(ix) Prevent skin diseases in the context of immunosuppression
(sun exposure)
(x) Share their projects and activities, express their fears, desires,
talk about body image, and manage stress, emotions, and so forth
(life skills).
(xi) Know the risks of travelling
be scheduled to help patients manage their time when they
resume work. Partners and close family members or friends
are of great help for transplant recipients and can be invited
to attend some of the education sessions.
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